A. The bites and stings of insects, spiders, and other invertebrates have been the source of human pain, death, and fear throughout history. Yet the same toxic compounds that make these animals dangerous have, in many cases, also attracted the attention of medical researchers looking for new drugs, antimicrobial agents, and tools for understanding the nervous system. The venom of the cone snail, the saliva of the bloodsucking tick, and the complex cocktail of compounds in bee venom have all contributed to the development of clinically useful medications or to fundamental scientific discoveries about the mechanisms of pain, blood clotting, and cellular communication. The systematic investigation of invertebrate toxins has emerged as a productive field at the intersection of pharmacology, evolutionary biology, and natural product chemistry.
B. Mosquitoes — responsible for more human deaths than any other animal through their role in transmitting diseases including malaria, dengue fever, yellow fever, and Zika — might seem unlikely candidates for medical benefit. Yet the saliva that a mosquito injects when it bites contains a remarkable array of pharmacological compounds designed to prevent blood clotting and suppress the host's immune response while the insect feeds. Components of mosquito saliva that inhibit platelet aggregation — the process through which blood begins to form a clot at a wound site — have been investigated as potential anticoagulant drugs for preventing thrombosis, and there is active research interest in compounds that modulate immune responses in ways that might be applicable to treating inflammatory conditions.
C. Bee venom has perhaps the longest history of medical use of any insect-derived product. Apitherapy — the therapeutic use of bee stings — has been practised in traditional medicine in China, Korea, and Eastern Europe for centuries, most commonly for the treatment of arthritis and other inflammatory conditions. The principal bioactive component of bee venom is melittin, a small peptide that disrupts cell membranes and produces the pain and local inflammation associated with bee stings. In laboratory settings, melittin has shown activity against a range of pathogens including HIV, bacteria resistant to conventional antibiotics, and cancer cells. Delivering melittin selectively to target cells without harming normal tissue remains a major challenge, and clinical translation has been slow despite decades of research.
D. The saliva of blood-sucking arthropods — including ticks, leeches, and sandflies as well as mosquitoes — has been a particularly rich source of pharmacologically active compounds, since these organisms have evolved over millions of years to overcome the same haemostatic and immune mechanisms that pharmaceutical researchers are trying to modulate therapeutically. Eptifibatide, an antiplatelet drug derived from the venom of the pygmy rattlesnake and used to prevent blood clots during cardiac procedures, illustrates how molecules evolved for predatory or parasitic purposes can be repurposed as therapeutic agents. Hirudin, the anticoagulant produced by medicinal leeches, was the first blood-thinning agent isolated in pure form and provided the pharmacological model for several synthetic anticoagulants now in clinical use.
E. The cone snail — a group of marine gastropod molluscs that hunt fish, worms, and other molluscs using a harpoon-like radula to inject venom — has provided one of the most clinically successful compounds to emerge from invertebrate toxin research. Ziconotide, derived from a component of cone snail venom, is approved for the treatment of severe chronic pain in patients who have not responded to opioids or other conventional analgesics. It acts by blocking a specific type of calcium channel in pain-transmitting neurons, producing powerful analgesia without the tolerance and addiction risks associated with opioid drugs. The discovery and development of ziconotide illustrates both the therapeutic potential of invertebrate toxins and the technical challenges involved in identifying and characterising the active components of complex venoms.
F. The systematic investigation of invertebrate venoms has been transformed by advances in genomics, proteomics, and high-throughput screening technologies. It is now possible to sequence the venom gland transcriptome of a single specimen, identifying the genes encoding all the proteins and peptides present in the venom without the need for large quantities of biological material. High-throughput bioassay platforms allow thousands of venom-derived compounds to be tested simultaneously against panels of molecular targets relevant to human disease. These advances have dramatically accelerated the rate at which novel bioactive compounds can be identified and characterised, and the growing inventory of known invertebrate venoms — which includes thousands of species whose venoms have never been systematically investigated — represents a vast and largely untapped resource for drug discovery.